(EMN) Eastman Chemical - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2774321002
Stock:
Total Rating 37
Risk 83
Buy Signal -0.23
| Risk 5d forecast | |
|---|---|
| Volatility | 35.5% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -37.33 |
| Character TTM | |
|---|---|
| Beta | 1.083 |
| Beta Downside | 1.718 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.40% |
| CAGR/Max DD | -0.02 |
EPS (Earnings per Share)
Revenue
Description: EMN Eastman Chemical
Eastman Chemical Company operates as a specialty materials company in the United States, China, and internationally. The company's Additives & Functional Products segment offers amine derivative-based building blocks, intermediates for surfactants, metam-based soil fumigants, and organic acid-based solutions; specialty coalescent and solvents, paint additives, and specialty polymers; and heat transfer and aviation fluids. It serves transportation, personal care, wellness, food, feed, agriculture, building and construction, water treatment, energy, consumables, durables, and electronics markets. Its Advanced Materials segment provides copolyesters, cellulosic biopolymers, polyvinyl butyral sheets, polyester films and window and protective films for value-added end uses in the transportation, durables, electronics, building and construction, medical and pharma, and consumables end-markets. The company's Chemical Intermediates segment offers olefin and acetyl derivatives, methylamines and salts, higher amines and solvents, ethylene, and commodity solvents; and primary non-phthalate and phthalate plasticizers, and niche non-phthalate plasticizers for industrial chemicals and processing, building and construction, health and wellness, and food and feed. Its Fibers segment provides cellulose acetate tow, triacetin, cellulose acetate flake, acetic acid, and acetic anhydride for use in filtration media primarily cigarette filters; natural and solution dyed acetate yarns, and staple fiber for use in consumables, and health and wellness markets; and wet-laid nonwoven media, specialty and engineered papers, and cellulose acetate fibers for transportation, industrial, agriculture and mining, and aerospace markets. Eastman Chemical Company was founded in 1920 and is headquartered in Kingsport, Tennessee.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 474.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.67 > 1.0 |
| NWC/Revenue: 11.35% < 20% (prev 14.85%; Δ -3.50% < -1%) |
| CFO/TA 0.07 > 3% & CFO 970.0m > Net Income 474.0m |
| Net Debt (4.51b) to EBITDA (1.30b): 3.48 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.9m) vs 12m ago -2.54% < -2% |
| Gross Margin: 21.07% > 18% (prev 0.24%; Δ 2083 % > 0.5%) |
| Asset Turnover: 58.21% > 50% (prev 61.67%; Δ -3.46% > 0%) |
| Interest Coverage Ratio: 3.62 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 217.0m) |
Altman Z'' 4.19
| A: 0.07 (Total Current Assets 3.65b - Total Current Liabilities 2.65b) / Total Assets 14.86b |
| B: 0.68 (Retained Earnings 10.11b / Total Assets 14.86b) |
| C: 0.05 (EBIT TTM 785.0m / Avg Total Assets 15.04b) |
| D: 1.13 (Book Value of Equity 9.95b / Total Liabilities 8.82b) |
| Altman-Z'' Score: 4.19 = AA |
Beneish M -3.04
| DSRI: 0.91 (Receivables 999.0m/1.17b, Revenue 8.75b/9.38b) |
| GMI: 1.16 (GM 21.07% / 24.41%) |
| AQI: 0.99 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.93 (Revenue 8.75b / 9.38b) |
| TATA: -0.03 (NI 474.0m - CFO 970.0m) / TA 14.86b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of EMN shares?
As of March 02, 2026, the stock is trading at USD 75.51 with a total of 1,231,107 shares traded.
Over the past week, the price has changed by -1.38%, over one month by +5.64%, over three months by +23.48% and over the past year by -16.37%.
Over the past week, the price has changed by -1.38%, over one month by +5.64%, over three months by +23.48% and over the past year by -16.37%.
Is EMN a buy, sell or hold?
Eastman Chemical has received a consensus analysts rating of 4.15.
Therefore, it is recommended to buy EMN.
- StrongBuy: 10
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.6 | 1.4% |
| Analysts Target Price | 76.6 | 1.4% |
EMN Fundamental Data Overview February 28, 2026
P/E Trailing = 18.3463
P/E Forward = 9.3985
P/S = 0.9804
P/B = 1.2668
P/EG = 3.1324
Revenue TTM = 8.75b USD
EBIT TTM = 785.0m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 4.20b USD (from longTermDebt, last quarter)
Short Term Debt = 642.0m USD (from shortTermDebt, last quarter)
Debt = 5.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.51b USD (from netDebt column, last quarter)
Enterprise Value = 13.09b USD (8.58b + Debt 5.08b - CCE 566.0m)
Interest Coverage Ratio = 3.62 (Ebit TTM 785.0m / Interest Expense TTM 217.0m)
EV/FCF = 30.88x (Enterprise Value 13.09b / FCF TTM 424.0m)
FCF Yield = 3.24% (FCF TTM 424.0m / Enterprise Value 13.09b)
FCF Margin = 4.84% (FCF TTM 424.0m / Revenue TTM 8.75b)
Net Margin = 5.42% (Net Income TTM 474.0m / Revenue TTM 8.75b)
Gross Margin = 21.07% ((Revenue TTM 8.75b - Cost of Revenue TTM 6.91b) / Revenue TTM)
Gross Margin QoQ = 17.13% (prev 19.66%)
Tobins Q-Ratio = 0.88 (Enterprise Value 13.09b / Total Assets 14.86b)
Interest Expense / Debt = 1.02% (Interest Expense 52.0m / Debt 5.08b)
Taxrate = 16.37% (93.0m / 568.0m)
NOPAT = 656.5m (EBIT 785.0m * (1 - 16.37%))
Current Ratio = 1.37 (Total Current Assets 3.65b / Total Current Liabilities 2.65b)
Debt / Equity = 0.85 (Debt 5.08b / totalStockholderEquity, last quarter 5.96b)
Debt / EBITDA = 3.48 (Net Debt 4.51b / EBITDA 1.30b)
Debt / FCF = 10.64 (Net Debt 4.51b / FCF TTM 424.0m)
Total Stockholder Equity = 5.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.15% (Net Income 474.0m / Total Assets 14.86b)
RoE = 8.09% (Net Income TTM 474.0m / Total Stockholder Equity 5.86b)
RoCE = 7.80% (EBIT 785.0m / Capital Employed (Equity 5.86b + L.T.Debt 4.20b))
RoIC = 6.04% (NOPAT 656.5m / Invested Capital 10.86b)
WACC = 6.54% (E(8.58b)/V(13.66b) * Re(9.90%) + D(5.08b)/V(13.66b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 9.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.61%
[DCF] Terminal Value 84.86% ; FCFF base≈529.6m ; Y1≈587.9m ; Y5≈767.2m
[DCF] Fair Price = 123.8 (EV 18.63b - Net Debt 4.51b = Equity 14.12b / Shares 114.0m; r=6.54% [WACC]; 5y FCF grow 12.71% → 2.90% )
EPS Correlation: -39.81 | EPS CAGR: -23.62% | SUE: 0.21 | # QB: 0
Revenue Correlation: -79.37 | Revenue CAGR: -8.11% | SUE: -0.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.63 | Chg7d=-0.001 | Chg30d=-0.024 | Revisions Net=-2 | Analysts=14
EPS current Year (2026-12-31): EPS=5.82 | Chg7d=-0.006 | Chg30d=-0.236 | Revisions Net=-13 | Growth EPS=+7.3% | Growth Revenue=+0.8%
EPS next Year (2027-12-31): EPS=6.73 | Chg7d=+0.000 | Chg30d=-0.274 | Revisions Net=-8 | Growth EPS=+15.7% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 9.9% - Earnings Yield 5.5%)
[Growth] Growth Spread = -4.8% (Analyst -0.4% - Implied 4.4%)
P/E Forward = 9.3985
P/S = 0.9804
P/B = 1.2668
P/EG = 3.1324
Revenue TTM = 8.75b USD
EBIT TTM = 785.0m USD
EBITDA TTM = 1.30b USD
Long Term Debt = 4.20b USD (from longTermDebt, last quarter)
Short Term Debt = 642.0m USD (from shortTermDebt, last quarter)
Debt = 5.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.51b USD (from netDebt column, last quarter)
Enterprise Value = 13.09b USD (8.58b + Debt 5.08b - CCE 566.0m)
Interest Coverage Ratio = 3.62 (Ebit TTM 785.0m / Interest Expense TTM 217.0m)
EV/FCF = 30.88x (Enterprise Value 13.09b / FCF TTM 424.0m)
FCF Yield = 3.24% (FCF TTM 424.0m / Enterprise Value 13.09b)
FCF Margin = 4.84% (FCF TTM 424.0m / Revenue TTM 8.75b)
Net Margin = 5.42% (Net Income TTM 474.0m / Revenue TTM 8.75b)
Gross Margin = 21.07% ((Revenue TTM 8.75b - Cost of Revenue TTM 6.91b) / Revenue TTM)
Gross Margin QoQ = 17.13% (prev 19.66%)
Tobins Q-Ratio = 0.88 (Enterprise Value 13.09b / Total Assets 14.86b)
Interest Expense / Debt = 1.02% (Interest Expense 52.0m / Debt 5.08b)
Taxrate = 16.37% (93.0m / 568.0m)
NOPAT = 656.5m (EBIT 785.0m * (1 - 16.37%))
Current Ratio = 1.37 (Total Current Assets 3.65b / Total Current Liabilities 2.65b)
Debt / Equity = 0.85 (Debt 5.08b / totalStockholderEquity, last quarter 5.96b)
Debt / EBITDA = 3.48 (Net Debt 4.51b / EBITDA 1.30b)
Debt / FCF = 10.64 (Net Debt 4.51b / FCF TTM 424.0m)
Total Stockholder Equity = 5.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.15% (Net Income 474.0m / Total Assets 14.86b)
RoE = 8.09% (Net Income TTM 474.0m / Total Stockholder Equity 5.86b)
RoCE = 7.80% (EBIT 785.0m / Capital Employed (Equity 5.86b + L.T.Debt 4.20b))
RoIC = 6.04% (NOPAT 656.5m / Invested Capital 10.86b)
WACC = 6.54% (E(8.58b)/V(13.66b) * Re(9.90%) + D(5.08b)/V(13.66b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 9.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.61%
[DCF] Terminal Value 84.86% ; FCFF base≈529.6m ; Y1≈587.9m ; Y5≈767.2m
[DCF] Fair Price = 123.8 (EV 18.63b - Net Debt 4.51b = Equity 14.12b / Shares 114.0m; r=6.54% [WACC]; 5y FCF grow 12.71% → 2.90% )
EPS Correlation: -39.81 | EPS CAGR: -23.62% | SUE: 0.21 | # QB: 0
Revenue Correlation: -79.37 | Revenue CAGR: -8.11% | SUE: -0.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.63 | Chg7d=-0.001 | Chg30d=-0.024 | Revisions Net=-2 | Analysts=14
EPS current Year (2026-12-31): EPS=5.82 | Chg7d=-0.006 | Chg30d=-0.236 | Revisions Net=-13 | Growth EPS=+7.3% | Growth Revenue=+0.8%
EPS next Year (2027-12-31): EPS=6.73 | Chg7d=+0.000 | Chg30d=-0.274 | Revisions Net=-8 | Growth EPS=+15.7% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 9.9% - Earnings Yield 5.5%)
[Growth] Growth Spread = -4.8% (Analyst -0.4% - Implied 4.4%)